PMID- 23688003
OWN - NLM
STAT- MEDLINE
DCOM- 20140110
LR  - 20211021
IS  - 1471-2490 (Electronic)
IS  - 1471-2490 (Linking)
VI  - 13
DP  - 2013 May 21
TI  - Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma.
PG  - 26
LID - 10.1186/1471-2490-13-26 [doi]
AB  - BACKGROUND: Renal cell carcinoma (RCC) is a histopathologically and molecularly 
      heterogeneous disease with the chromophobe subtype (chRCC) accounting for 
      approximately 5% of all cases. The median overall survival of advanced RCC has 
      improved significantly since the advent of tyrosine kinase inhibitors and 
      mammalian target of rapamycin (mTOR) inhibitors. However, high-quality evidence 
      for the use of new generation tyrosine kinase inhibitors in patients with 
      advanced chRCC is lacking. Few published case reports have highlighted the use of 
      temsirolimus in chRCC. CASE PRESENTATION: Here, we report the case of a 
      36-year-old Caucasian woman with metastatic chRCC with predominantly skeletal 
      metastases who was refractory to sunitinib who demonstrated a durable clinical 
      response to temsirolimus lasting 20 months. We review the available evidence 
      pertaining to the use of new generation molecularly targeted agents, in 
      particular mTOR inhibitors in chRCC and discuss their emerging role in the 
      management of this disease which would aid the oncologists faced with the 
      challenge of treating this rare type of RCC. CONCLUSION: Conducting randomised 
      clinical trials in this rarer sub-group of patients would be challenging and our 
      case report and the evidence reviewed would guide the physicians to make informed 
      decision regarding the management of these patients.
FAU - Venugopal, Balaji
AU  - Venugopal B
AD  - Beatson West of Scotland Cancer Centre, 1053, Great Western Road, Glasgow G12 
      0YN, UK. balajivenugopal@nhs.net
FAU - Ansari, Jawaher
AU  - Ansari J
FAU - Aitchison, Michael
AU  - Aitchison M
FAU - Tho, Lye Mun
AU  - Tho LM
FAU - Campbell, Roderick
AU  - Campbell R
FAU - Jones, Rob J
AU  - Jones RJ
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130521
PL  - England
TA  - BMC Urol
JT  - BMC urology
JID - 100968571
RN  - 0 (Antineoplastic Agents)
RN  - 624KN6GM2T (temsirolimus)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Adult
MH  - Antineoplastic Agents/therapeutic use
MH  - Bone Neoplasms/*drug therapy/pathology/*secondary
MH  - Carcinoma, Renal Cell/*drug therapy/pathology/*secondary
MH  - Female
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy/*pathology
MH  - Sirolimus/*analogs & derivatives/therapeutic use
MH  - Treatment Outcome
PMC - PMC3679738
EDAT- 2013/05/22 06:00
MHDA- 2014/01/11 06:00
PMCR- 2013/05/21
CRDT- 2013/05/22 06:00
PHST- 2012/06/18 00:00 [received]
PHST- 2013/05/15 00:00 [accepted]
PHST- 2013/05/22 06:00 [entrez]
PHST- 2013/05/22 06:00 [pubmed]
PHST- 2014/01/11 06:00 [medline]
PHST- 2013/05/21 00:00 [pmc-release]
AID - 1471-2490-13-26 [pii]
AID - 10.1186/1471-2490-13-26 [doi]
PST - epublish
SO  - BMC Urol. 2013 May 21;13:26. doi: 10.1186/1471-2490-13-26.